keyword
MENU ▼
Read by QxMD icon Read
search

ki67 residual breast cancer

keyword
https://www.readbyqxmd.com/read/27113745/cyr61-contributes-to-poor-response-to-letrozole-in-er-positive-breast-carcinoma
#1
Xiaoqing Jia, Guangyu Liu, Jingyi Cheng, Zhenzhou Shen, Zhimin Shao
Studies have demonstrated that cysteine-rich 61 (CYR61) may be involved in tumor proliferation and invasion. However, little is known about the role of CYR61 plays in endocrine therapy. Here, we tested the CYR61 expression on human tissues from 36 primary breast cancer patients by immunohistochemistry staining before and after administrating letrozole , an oral non-steroidal aromatase inhibitor (AI) for the treatment of hormone-responsive breast cancer. The expression levels of CYR61 and ki67 were analyzed between pre-treatment and post-treatment samples by using the paired t test...
April 26, 2016: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/26338270/impact-of-biomarker-changes-during-neoadjuvant-chemotherapy-for-clinical-response-in-patients-with-residual-breast-cancers
#2
Yukie Enomoto, Takashi Morimoto, Arisa Nishimukai, Tomoko Higuchi, Ayako Yanai, Yoshimasa Miyagawa, Keiko Murase, Michiko Imamura, Yuichi Takatsuka, Takashi Nomura, Masashi Takeda, Takahiro Watanabe, Seiichi Hirota, Yasuo Miyoshi
BACKGROUND: Residual cancer burden or Ki67 expression levels in residual tumors reportedly provided significant prognostic information for a non-pathological complete response subset after neoadjuvant chemotherapy (NAC). However, the significance of Ki67 reduction for clinical response during chemotherapy in each subtype or menopausal status is yet to be determined. METHODS: A total of 183 breast cancers surgically removed after chemotherapy were recruited for this study...
April 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26255746/neoadjuvant-endocrine-therapy-patient-selection-treatment-duration-and-surrogate-endpoints
#3
Belinda Yeo, Mitch Dowsett
Neoadjuvant endocrine treatment has become of increasing interest for downstaging primary ER+ breast cancers as it has become clear that the pathologic complete response rate of luminal tumours to chemotherapy is much lower than that of non-luminal and differs little from that to endocrine therapy. There is much more experience in postmenopausal than premenopausal women. Aromatase inhibitors are generally the agent of choice. Responses are lower in those with the low levels of ER. While duration of endocrine treatment in clinical trials has usually been standardized at around three to four months it is clear that volume reductions continue to occur beyond that time in a large proportion of cases and routine clinical practice is often to treat to maximum response...
November 2015: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/26245675/prospective-biomarker-analysis-of-the-randomized-cher-lob-study-evaluating-the-dual-anti-her2-treatment-with-trastuzumab-and-lapatinib-plus-chemotherapy-as-neoadjuvant-therapy-for-her2-positive-breast-cancer
#4
RANDOMIZED CONTROLLED TRIAL
Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, Antonino Maiorana, Guido Ficarra, Stefania Bettelli, Enrico Tagliafico, Silvio Bicciato, Daniele Giulio Generali, Katia Cagossi, Giancarlo Bisagni, Samanta Sarti, Antonino Musolino, Catherine Ellis, Rocco Crescenzo, PierFranco Conte
BACKGROUND: The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. A biomarker program was prospectively planned to identify potential predictors of sensitivity to different treatments and to evaluate treatment effect on tumor biomarkers. MATERIALS AND METHODS: Overall, 121 breast cancer patients positive for human epidermal growth factor 2 (HER2) were randomly assigned to neoadjuvant chemotherapy plus trastuzumab, lapatinib, or both trastuzumab and lapatinib...
September 2015: Oncologist
https://www.readbyqxmd.com/read/26178788/biological-effects-of-fulvestrant-on-estrogen-receptor-positive-human-breast-cancer-short-medium-and-long-term-effects-based-on-sequential-biopsies
#5
Amit Agrawal, John F R Robertson, Kwok L Cheung, Eleanor Gutteridge, Ian O Ellis, Robert I Nicholson, Julia M W Gee
We report the first study of the biological effect of fulvestrant on ER positive clinical breast cancer using sequential biopsies through to progression. Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity. This series showed good fulvestrant responses (duration of response [DoR] = 25.8 months; clinical benefit = 81%)...
January 1, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/26063881/early-surrogate-markers-of-treatment-activity-where-are-we-now
#6
Marie Klintman, Mitchell Dowsett
The assessment of new therapies in the adjuvant setting in early breast cancer requires large numbers of patients and many years of follow-up for results to be presented. Therefore, the neoadjuvant study setting, which allows for early prediction of treatment response in smaller patient sets, has become increasingly popular. Ki67 is the most commonly used and extensively studied intermediate biomarker of treatment activity and residual risk in neoadjuvant trials on endocrine therapy, new biological therapies, and chemotherapy...
May 2015: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/25673053/%C3%A2-%C3%A2-f-flt-pet-ct-as-an-imaging-tool-for-early-prediction-of-pathological-response-in-patients-with-locally-advanced-breast-cancer-treated-with-neoadjuvant-chemotherapy-a-pilot-study
#7
Flavio Crippa, Roberto Agresti, Marco Sandri, Gabriella Mariani, Barbara Padovano, Alessandra Alessi, Giulia Bianchi, Emilio Bombardieri, Ilaria Maugeri, Mario Rampa, Maria Luisa Carcangiu, Giovanna Trecate, Claudio Pascali, Anna Bogni, Gabriele Martelli, Filippo de Braud
PURPOSE: We evaluated whether (18)F-3'-deoxy-3'-fluorothymidine positron emission tomography (FLT PET) can predict the final postoperative histopathological response in primary breast cancer after the first cycle of neoadjuvant chemotherapy (NCT). METHODS: In this prospective cohort study of 15 patients with locally advanced operable breast cancer, FLT PET evaluations were performed before NCT, after the first cycle of NCT, and at the end of NCT. All patients subsequently underwent surgery...
May 2015: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/25400769/prognostic-value-of-ki67-expression-in-hr-negative-breast-cancer-before-and-after-neoadjuvant-chemotherapy
#8
Qi-Xing Tan, Qing-Hong Qin, Wei-Ping Yang, Qin-Guo Mo, Chang-Yuan Wei
BACKGROUND: Immunohistochemical (IHC) expression of Ki67 has been identified as a prognostic and predictive marker in hormone receptor (HR)-positive breast cancer, however, there is little evidence of the association of Ki67 with prognosis in HR-negative patients. We aimed to assess the benefit of Ki67 assessment in HR-negative breast cancers after neoadjuvant chemotherapy (NAC). METHODS: In the present study, a total of 183 HR-negative breast cancer patients with Stage II to III that treated with anthracycline and/or taxane-based neoadjuvant chemotherapy between 2004 and 2011 were retrospectively analyzed...
2014: International Journal of Clinical and Experimental Pathology
https://www.readbyqxmd.com/read/25361988/residual-proliferative-cancer-burden-to-predict-long-term-outcome-following-neoadjuvant-chemotherapy
#9
A Sheri, I E Smith, S R Johnston, R A'Hern, A Nerurkar, R L Jones, M Hills, S Detre, S E Pinder, W F Symmans, M Dowsett
BACKGROUND: The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the residual proliferative cancer burden (RPCB), provides significantly more prognostic information than either alone; (ii) to determine whether also integrating information on ER and grade improves prognostic power. PATIENTS AND METHODS: A total of 220 patients treated with neoadjuvant chemotherapy for primary breast cancer were included in the study...
January 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/25241216/her-2-positive-breast-cancer-is-associated-with-an-increased-risk-of-positive-cavity-margins-after-initial-lumpectomy
#10
Haixia Jia, Weijuan Jia, Yaping Yang, Shunrong Li, Huiyi Feng, Jieqiong Liu, Nanyan Rao, Liang Jin, Jiannan Wu, Ru Gu, Liling Zhu, Kai Chen, Heran Deng, Yunjie Zeng, Qiang Liu, Erwei Song, Fengxi Su
BACKGROUND: The effect of breast cancer subtype on margin status after lumpectomy remains unclear. This study aims to determine whether approximated breast cancer subtype is associated with positive margins after lumpectomy, which could be used to determine if there is an increased risk of developing local recurrence (LR) following breast-conserving surgery. METHODS: We studied 1,032 consecutive patients with invasive cancer who received lumpectomies and cavity margin (CM) assessments from January 2003 to November 2012...
2014: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/25221644/cdk4-6-inhibition-provides-a-potent-adjunct-to-her2-targeted-therapies-in-preclinical-breast-cancer-models
#11
Agnieszka K Witkiewicz, Derek Cox, Erik S Knudsen
In spite of the efficacy of Her2-targeted therapies, recurrence and progression remain a challenge for treatment of Her2 positive breast cancer. CDK4/6 controls pathway downstream of Her2, Inhibition of these kinases could represent an important therapeutic approach to augment the effectiveness of standard therapies. In models of acquired resistance to Her2-targeted therapies, Cyclin D1 was inappropriately activated and CDK4/6 inhibition was effective at blocking proliferation by targeting this common pathway associated with resistance...
July 2014: Genes & Cancer
https://www.readbyqxmd.com/read/24762066/changes-in-aldehyde-dehydrogenase-1-expression-during-neoadjuvant-chemotherapy-predict-outcome-in-locally-advanced-breast-cancer
#12
RANDOMIZED CONTROLLED TRIAL
Muhammad Alamgeer, Vinod Ganju, Beena Kumar, Jane Fox, Stewart Hart, Michelle White, Marion Harris, John Stuckey, Zdenka Prodanovic, Michal Elisabeth Schneider-Kolsky, D Neil Watkins
INTRODUCTION: Although neoadjuvant chemotherapy (NAC) for locally advanced breast cancer can improve operability and local disease control, there is a lack of reliable biomarkers that predict response to chemotherapy or long-term survival. Since expression of aldehyde dehydrogenase-1 (ALDH1) is associated with the stem-like properties of self-renewal and innate chemoresistance in breast cancer, we asked whether expression in serial tumor samples treated with NAC could identify women more likely to benefit from this therapy...
2014: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/24719175/pretreatment-vitamin-d-level-and-response-to-neoadjuvant-chemotherapy-in-women-with-breast-cancer-on-the-i-spy-trial-calgb-150007-150015-acrin6657
#13
Amy S Clark, Jinbo Chen, Shiv Kapoor, Claire Friedman, Carolyn Mies, Laura Esserman, Angela DeMichele
Laboratory studies suggest that vitamin D (vitD) enhances chemotherapy-induced cell death. The objective of this study was to determine whether pretreatment vitD levels were associated with response to neoadjuvant chemotherapy (NACT) in women with breast cancer. Study patients (n = 82) were enrolled on the I-SPY TRIAL, had HER2-negative tumors, and available pretreatment serum. VitD levels were measured via DiaSorin radioimmunoassay. The primary outcome was pathologic residual cancer burden (RCB; dichotomized 0/1 vs...
June 2014: Cancer Medicine
https://www.readbyqxmd.com/read/23852223/immunohistochemical-bag1-expression-improves-the-estimation-of-residual-risk-by-ihc4-in-postmenopausal-patients-treated-with-anastrazole-or-tamoxifen-a-transatac-study
#14
Maria Afentakis, Mitch Dowsett, Ivana Sestak, Janine Salter, Tony Howell, Aman Buzdar, John Forbes, Jack Cuzick
BAG1 is a multifunctional anti-apoptotic protein located on chromosome 9q12, which binds to Bcl-2. BAG1 is present as a separate module in the GHI-RS 21-gene panel. It may provide additional prognostic information as an immunohistochemical marker when added to IHC4. Analysis of BAG1 was performed on archival tumour blocks from patients from the anastrozole and tamoxifen arms of the ATAC trial of 5 years endocrine therapy in postmenopausal women with oestrogen receptor (ER)-positive primary breast cancer. Staining was scored separately as nuclear or cytoplasmic...
July 2013: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/23812670/ki67-measured-after-neoadjuvant-chemotherapy-for-primary-breast-cancer
#15
Gunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, Berit M Müller, Jens U Blohmer, Bruno V Sinn, Holger Eidtmann, Wolfgang Eiermann, Bernd Gerber, Hans Tesch, Jörn Hilfrich, Jens Huober, Tanja Fehm, Jana Barinoff, Thomas Rüdiger, Erhard Erbstoesser, Peter A Fasching, Thomas Karn, Volkmar Müller, Christian Jackisch, Carsten Denkert
PURPOSE: The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described. EXPERIMENTAL DESIGN: Participants of the GeparTrio study with primary breast cancer randomly received neoadjuvant response-guided [8 cycles TAC (docetaxel/doxorubicin/cyclophosphamide) in responding and TAC-NX (vinorelbine/capecitabine) in nonresponding patients] or conventional (6 cycles TAC) chemotherapy according to interim response assessment...
August 15, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/23685463/reconstruction-with-cutaneous-flap-after-resection-for-breast-cancer-s-skin-metastases-in-a-chemoresistant-patient
#16
Antonio Varricchio, Lorenzo Di Libero, Carlo Iannace
We reported a case of a breast cancer's skin metastases in a patient that had sustained 3 lines of chemotherapy. At first she received surgical treatment with Madden's mastectomy with dissection of axillary limphnodes and positioning of an expander. After that she underwent to chemo- and radiotherapy. The schedules we performed were: FEC, TC,Vinorelbine and Capecitabine. Only after the FEC there was a clinical remission just for 1 year. After that she underwent to surgery for the removal of a lozenge of skin on the right hemithorax, including also the subcutaneous tissue, a strip of muscular tissue, and a residue of the breast implant...
2013: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/23645542/prognostic-significance-of-pathologic-complete-response-and-ki67-expression-after-neoadjuvant-chemotherapy-in-breast-cancer
#17
Tatsuya Yoshioka, Mitsuchika Hosoda, Mitsugu Yamamoto, Kazunori Taguchi, Kanako C Hatanaka, Emi Takakuwa, Yutaka Hatanaka, Yoshihiro Matsuno, Hiroko Yamashita
BACKGROUND: Recent studies have indicated that response to chemotherapy and the prognostic impact of a pathologic complete response (pCR) after neoadjuvant chemotherapy differ among breast cancer subtypes. METHODS: Women with Stage I to III breast cancer treated with anthracycline and taxane-based neoadjuvant chemotherapy (four cycles of docetaxel every 3 weeks followed by four cycles of FEC every 3 weeks) between 2006 and 2011 were retrospectively analyzed. Trastuzumab was concurrently added to docetaxel for HER2-positive breast cancer...
March 2015: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/23374644/the-potential-prognostic-value-of-connexin-26-and-46-expression-in-neoadjuvant-treated-breast-cancer
#18
Ivett Teleki, Tibor Krenacs, Marcell A Szasz, Janina Kulka, Barna Wichmann, Cornelia Leo, Barbel Papassotiropoulos, Cosima Riemenschnitter, Holger Moch, Zsuzsanna Varga
BACKGROUND: Several classification systems are available to assess pathological response to neoadjuvant chemotherapy in breast cancer, but reliable biomarkers to predict the efficiency of primary systemic therapy (PST) are still missing. Deregulation of gap junction channel forming connexins (Cx) has been implicated in carcinogenesis and tumour progression through loss of cell cycle control. In this study we correlated Cx expression and cell proliferation with disease survival and pathological response to neoadjuvant chemotherapy in breast cancers using existing classification systems...
February 2, 2013: BMC Cancer
https://www.readbyqxmd.com/read/23291072/-phase-ii-clinical-trial-of-neoadjuvant-therapy-with-carboplatin-plus-paclitaxel-for-locally-advanced-triple-negative-breast-cancer
#19
Wen-yue Ma, Pin Zhang, Bai-lin Zhang, Xiang Wang, Xiao-zhou Xu, Shan Zheng, Jia-yu Wang, Rui-gang Cai, Peng Yuan, Fei Ma, Ying Fan, Bing-he Xu
OBJECTIVE: To evaluate the efficacy, safety and survival of combination of carboplatin plus paclitaxel as neoadjuvant chemotherapy (NACT) for patients with locally advanced triple-negative breast cancer (TNBC), and explore an optimal regimen for TNBC. METHODS: Patients with core needle biopsy confirmed pathological diagnosis of IIA ∼ IIIC invasive breast cancer, negative for estrogen and progesterone receptors and HER2 by immunohistochemistry, and with indication for NACT were eligible in this study...
October 2012: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/22987966/developments-in-ki67-and-other-biomarkers-for-treatment-decision-making-in-breast-cancer
#20
A Sheri, M Dowsett
Estrogen receptor (ER) and HER2 are well established as predictive markers for treatment benefit, although methodological deficiencies can still affect their predictive accuracy. The shift towards earlier diagnosis poses a challenge in identifying those low-risk patients who may safely avoid adjuvant chemotherapy for early breast cancer. Therefore, recent research has focused on developing biomarkers to quantify residual risk on adjuvant endocrine therapy. For widespread adoption into clinical practice, these must be validated in well-designed clinical trials and provide additional information to current standards using reproducible and cost-effective methodologies...
September 2012: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
99219
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"